Get the Stockscreener App
0.2449
3.77%
0.0089
After Hours:
.24
-0.0049
-2.00%
Calidi Biotherapeutics Inc stock is traded at $0.2449, with a volume of 392.31K.
It is up +3.77% in the last 24 hours and down -32.10% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$0.236
Open:
$0.24
24h Volume:
392.31K
Relative Volume:
1.71
Market Cap:
$2.67M
Revenue:
-
Net Income/Loss:
$-25.74M
P/E Ratio:
-0.0496
EPS:
-4.938
Net Cash Flow:
$-21.41M
1W Performance:
+2.43%
1M Performance:
-32.10%
6M Performance:
-84.30%
1Y Performance:
-95.89%
1-Day Range:
$0.2301
$0.2518
1-Week Range:
$0.2102
$0.2518
52-Week Range:
$0.2088
$19.20
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.2449 | 2.57M | 0 | -25.74M | -21.41M | -4.938 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Calidi Biotherapeutics, Inc. (CLDI) stock price, news, quote and history - Yahoo Finance UK
Calidi Biotherapeutics to reduce board size as director term nears expiration By Investing.com - Investing.com Australia
Calidi Biotherapeutics (CLDI) Hinges on High-Stakes Q4 2026 IND Filing as Market Waits for Catalyst - Bitget
Calidi Biotherapeutics to reduce board size as director term nears expiration - Investing.com India
Calidi Biotherapeutics Streamlines Board, Enhances Audit Oversight - tipranks.com
Allan Camaisa to Leave Calidi Board; Scott Leftwich Joins Audit Committee - TradingView
Director transition leads Calidi Biotherapeutics (CLDI) to cut board size to five - Stock Titan
Calidi tees up new cancer-virus data before planned 2026 IND filing - Stock Titan
CLDI SEC FilingsCalidi Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 - Sahm
Calidi brings tumor-targeted immune therapy data to cancer meeting - Stock Titan
CLDI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Investor in Calidi Biotherapeutics (CLDI) discloses 0.3% stake - Stock Titan
VIX Spike: Is Calidi Biotherapeutics Inc forming a bullish divergenceWeekly Stock Summary & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Inflation Data: Is Calidi Biotherapeutics Inc forming a breakout pattern2026 Big Picture & Daily Entry Point Trade Alerts - baoquankhu1.vn
Calidi Biotherapeutics Reports 2025 Financial Results, Advances CLD-401 Clinical Development and Expands RedTail Platform Partnerships - Minichart
Calidi Biotherapeutics, Inc. 2025 Annual 10-K Report Highlights Equity, Warrants, and Financial Arrangements - Minichart
Calidi Biotherapeutics Reports 2025 Results, Advances Oncology Pipeline - TipRanks
Calidi 2025 10-K: $20.24M operating loss, $20.06M net loss, $5.6M cash - TradingView
Calidi Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Calidi Biotherapeutics (CLDI) 10-K shows going-concern risk and early oncology pipeline - stocktitan.net
Calidi Biotherapeutics (NYSE: CLDI) reports 2025 loss and $5.6M cash - stocktitan.net
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights - Bitget
Calidi Biotherapeutics released its financial results for the fourth quarter and full year of 2025, along with an update on its recent operational progress. - bitget.com
CALIDI Biotherapeutics Forms Partnership with Avance Clinical to Streamline Australian Regulatory Approval and Expedite CLD-401 Clinical Trials Launch - Intellectia AI
Market Pulse: Will Calidi Biotherapeutics Inc benefit from sector rotation2026 Breakouts & Breakdowns & Consistent Return Strategy Ideas - baoquankhu1.vn
Gap Down: Should I hold or sell Calidi Biotherapeutics Inc nowMarket Trend Review & Momentum Based Trading Signals - baoquankhu1.vn
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials - The Manila Times
Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval - TradingView
Calidi Biotherapeutics Announces Partnership with Avance - GlobeNewswire
CLDI Stock Price, Quote & Chart | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill
Calidi Biotherapeutics (CLDI) stock plunges 35% after hours — here's why - MSN
Calidi Biotherapeutics prices $5.2M underwritten public offering - MSN
Big Picture: Can Calidi Biotherapeutics Inc keep up with sector leaders2026 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn
Portfolio Recap: How much upside does Calidi Biotherapeutics Inc have2026 Market Mood & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing - Sahm
Calidi Biotherapeutics Prices Public Offering at $0.50 per Unit - Intellectia AI
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing - Bitget
How a tumor-targeting virus therapy earned FDA support on its production - Stock Titan
Calidi Biotherapeutics Announces Proposed Public Offering of Common Stock and Warrants to Fund Growth Initiatives 12 - Minichart
Calidi Biotherapeutics Completes Dilutive Public Equity Offering - TipRanks
Calidi Biotherapeutics announces underwritten public offering - Investing.com Nigeria
Calidi Biotherapeutics Raises $6.03 Million in Unit Offering; Adds Warrant Agent and Amends Legacy Warrants - TradingView
Calidi Biotherapeutics (NYSE: CLDI) closes $6M unit and warrant deal - Stock Titan
Portfolio Update: Is Calidi Biotherapeutics Inc a stock for growth or value investors2026 Trading Volume Trends & Accurate Buy Signal Alerts - baoquankhu1.vn
CLDI PE Ratio & Valuation, Is CLDI Overvalued - Intellectia AI
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option - Bitget
Calidi Biotherapeutics closes $6M public offering By Investing.com - Investing.com Canada
Calidi Biotherapeutics Announces Closing of $6.0 Million - GlobeNewswire
Calidi Biotherapeutics closes $6M public offering - Investing.com
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option - The Manila Times
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Calidi Biotherapeutics Inc Stock (CLDI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schoeneck James A | Director |
Aug 21 '25 |
Buy |
2.00 |
75,000 |
150,000 |
76,134 |
| Poma Eric E | Chief Executive Officer |
Aug 21 '25 |
Buy |
2.00 |
25,000 |
50,000 |
25,000 |
| Leftwich Scott | Director |
Aug 21 '25 |
Buy |
2.00 |
125,000 |
250,000 |
130,650 |
| Jackson Andrew C. | Chief Financial Officer |
Aug 21 '25 |
Buy |
2.00 |
2,500 |
5,000 |
2,500 |
0.87%
0.11%
Cap:
|
Volume (24h):